MX2021015137A - Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos. - Google Patents

Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos.

Info

Publication number
MX2021015137A
MX2021015137A MX2021015137A MX2021015137A MX2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A MX 2021015137 A MX2021015137 A MX 2021015137A
Authority
MX
Mexico
Prior art keywords
succinate prodrug
prodrug
compositions containing
succinate
nutricosmetics
Prior art date
Application number
MX2021015137A
Other languages
English (en)
Inventor
Steven James Moss
Matthew Alan Gregory
Alvar Grönberg
Magnus Joakim Hansson
Mats Eskil Elmér
Mark Richard Farmery
Lee Robert Webster
Original Assignee
Abliva Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abliva Ab filed Critical Abliva Ab
Publication of MX2021015137A publication Critical patent/MX2021015137A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención proporciona un nuevo profármaco de succinato aislado como el compuesto libre o una sal, hidrato, solvato o complejo del mismo que es permeable a las células y tiene como objetivo aumentar la producción de ATP en las mitocondrias. El compuesto es útil en el tratamiento médico de una variedad de enfermedades, en suplementos nutricionales, nutricosméticos y en cosméticos.
MX2021015137A 2019-06-19 2020-06-18 Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos. MX2021015137A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970384 2019-06-19
PCT/EP2020/066923 WO2020254484A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Publications (1)

Publication Number Publication Date
MX2021015137A true MX2021015137A (es) 2022-01-18

Family

ID=71130953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015137A MX2021015137A (es) 2019-06-19 2020-06-18 Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos.

Country Status (11)

Country Link
US (2) US11565998B2 (es)
EP (2) EP3986862B1 (es)
JP (1) JP2022538009A (es)
KR (1) KR20220024780A (es)
AU (1) AU2020298031A1 (es)
BR (1) BR112021024510A2 (es)
CA (1) CA3143112A1 (es)
IL (1) IL288990A (es)
MA (1) MA56506A (es)
MX (1) MX2021015137A (es)
WO (1) WO2020254484A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56506A (fr) * 2019-06-19 2022-04-27 Abliva Ab Promédicamentà base de succinate, compositions contenant le promédicament de succinate et utilisations associées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
RS57624B1 (sr) 2014-04-08 2018-11-30 Neurovive Pharmaceutical Ab Nova sukcinatna jedinjenja koja prodiru u ćelije
US10307389B2 (en) 2014-04-08 2019-06-04 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation
MA56506A (fr) * 2019-06-19 2022-04-27 Abliva Ab Promédicamentà base de succinate, compositions contenant le promédicament de succinate et utilisations associées

Also Published As

Publication number Publication date
EP4360708A2 (en) 2024-05-01
EP3986862A1 (en) 2022-04-27
WO2020254484A1 (en) 2020-12-24
BR112021024510A2 (pt) 2022-01-18
EP3986862B1 (en) 2024-01-24
US20230033294A1 (en) 2023-02-02
AU2020298031A1 (en) 2022-02-03
US11565998B2 (en) 2023-01-31
MA56506A (fr) 2022-04-27
CA3143112A1 (en) 2020-12-24
IL288990A (en) 2022-02-01
US20220162162A1 (en) 2022-05-26
JP2022538009A (ja) 2022-08-31
CN113993842A (zh) 2022-01-28
KR20220024780A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12020551305A1 (en) Pharmaceutical Compounds
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
AU2018231032A8 (en) JAK inhibitors containing a 4-membered heterocyclic amide
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
GEP20166484B (en) Protein kinase inhibitors
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
EA201790658A1 (ru) Производные диарилмочевины в качестве ингибиторов киназы p38
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
NZ745185A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2019011182A (es) Combinacion de derivados de isoindolinona con sgi-110.
PH12020550252A1 (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
MX2021015137A (es) Profarmaco de succinato, composiciones que contienen profarmaco de succinato y usos de los mismos.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.
AU2018337138A1 (en) 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
NZ784118A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2016199172A3 (en) 2,6-dicyano-anilines, 2-amino-7-cyano-benzopyrroles and iodobenzyl-1,2,3-triazoles as compounds for the treatment of cancer or for the imaging of cells
GB2553684A (en) Ethynylxanthines, preparation and use for cancer treatment